HighTower Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

HighTower Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,875	Closed	-$792K	–	3622
2023 Q4	$792K	Buy	12,875 +6,886	+115%	+$362K	﹤0.01%	1979
2023 Q3	$279K	Sell	5,989 -5,947	-50%	-$324K	﹤0.01%	2652
2023 Q2	$682K	Sell	11,936 -106	-0.9%	-$4.7K	﹤0.01%	1995
2023 Q1	$459K	Buy	12,042 +1,983	+20%	+$65K	﹤0.01%	2174
2022 Q4	$282K	Buy	+10,059	New	+$292K	﹤0.01%	2510

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

HighTower Advisors's AMPH Position: Q1 2024 in Review

HighTower Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 12,875 shares — an estimated $792K sold.

HighTower Advisors first reported a position in AMPH in Q4 2022 and held it in 5 quarters. The position peaked at $792K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

HighTower Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
HighTower Advisors sold 12,875 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $792K.
HighTower Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2022 and held it in 5 quarters.
HighTower Advisors's Amphastar Pharmaceuticals position peaked at $792K in Q4 2023.
270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.